DGDong Hyun Gim

Dong Hyun Gim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dong Hyun Gim has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Joo-Yong Hahn

    Sungkyunkwan University School of Medicine

    3 shared publications
  • Ki Hong Choi

    Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    3 shared publications
  • Young Bin Song

    Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    3 shared publications
  • Hyeon-Cheol Gwon

    Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    2 shared publications
  • Jeong Hoon Yang

    Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    2 shared publications
  • Joo Myung Lee

    Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    2 shared publications

Latest Publications

  • Clopidogrel Versus Aspirin Monotherapy According to Atherothrombotic Risk Profile

    by Joo Myung Lee, Dong Hyun Gim, Yong Hwan Park, Jong-Young Lee, Jin-Ok Jeong, Chan Joon Kim, Kyeong Ho Yun, Han Cheol Lee, Kiyuk Chang, Mahn-Won Park, et al.

    BACKGROUND: Clopidogrel monotherapy has shown superior efficacy compared with aspirin after completion of dual antiplatelet therapy following percutaneous coronary intervention (PCI). However, whether treatment effects differ according to overall atherothrombotic risk integrating clinical and angiographic factors remains unclear. METHODS: This post hoc analysis of the SMART-CHOICE 3 (Smart Angioplasty Research Team: Choice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3) randomized trial included patients who completed guideline-directed dual antiplatelet therapy after PCI. Atherothrombotic risk was defined using the a Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention and complex PCI. Patients with Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention ≥3 or complex PCI were classified as higher risk, and those with a Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention P =0.007). In higher-risk patients, clopidogrel reduced major adverse cardiac and cerebrovascular events compared with aspirin (4.6% versus 7.4%; hazard ratio, 0.67 [95% CI, 0.50–0.89]; P =0.006), with no difference in lower-risk patients (3.0% versus 3.2%; hazard ratio, 1.03; P =0.945; interaction P =0.242). Bleeding was similar between groups. CONCLUSIONS: After completion of dual antiplatelet therapy following PCI, clopidogrel monotherapy was associated with lower ischemic risk than aspirin in patients with higher atherothrombotic risk, without increased bleeding. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04418479.

  • Open Access

    Smoking Cessation, E-Cigarette Use, Continued Smoking, and Cardiovascular Outcomes after Diagnosis of Type 2 Diabetes: A Nationwide Cohort Study

    by Dong Hyun Gim, Yeonkyeong Han, Taegyun Park, Taek Kyu Park, Joo Myung Lee, Juhee Cho, Jeong Hoon Yang, Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi, et al.

    Background: Smoking cessation after a diagnosis of type 2 diabetes mellitus (T2DM) lowers cardiovascular risk, but sustained abstinence is difficult and e-cigarettes are promoted as an alternative. Whether switching to e-cigarettes confers comparable benefit is unknown.Methods: This nationwide cohort study used the Korean National Health Insurance Service database. Adults aged 40–74 years newly diagnosed with T2DM between Jan 1, 2018, and Dec 31, 2023, who smoked at the examination preceding diagnosis were included. Self-reported behaviour at the first examination after diagnosis (the index date) defined three groups: quitters, e-cigarette users, and continued combustible cigarette users. The primary outcome was myocardial infarction. Hazard ratios were estimated with Cox proportional hazards models weighted by stabilised inverse probability of treatment weights (IPTW). This study is registered with ClinicalTrials.gov, NCT07414355.Findings: Of 164,859 participants, 31,539 were quitters, 36,801 were e-cigarette users, and 96,519 continued smoking. Over a median 2·1 years (IQR:1·1–3·4), myocardial infarction occurred at 0·8, 1·4, and 1·7 events per 1000 person-years, respectively. Compared with quitters, risk was higher in e-cigarette users (IPTW-adjusted HR:1·78, 95%CI:1·21–2·62) and in continued smokers (HR:2·17, 95%CI:1·66–2·83); risk in e-cigarette users did not differ from that in continued smokers (HR:0·82, 95%CI:0·61–1·12). The pattern was similar for coronary revascularisation (HR:1·26, 95%CI:1·00–1·60 for e-cigarette users and HR:1·23, 95%CI:1·07–1·42 for continued smokers, respectively). Continued smokers also had higher risks of ischaemic stroke (HR:1·20, 95%CI:1·03–1·39) and all-cause death (HR:1·49, 95%CI:1·28–1·73), whereas estimates for e-cigarette users were 0·98 (95%CI:0·72–1·33) and 1·04 (95%CI:0·77–1·42). Dual users, who comprised 24,987 (67·9%) of e-cigarette users, had a higher myocardial infarction risk than complete switchers (HR:2·03, 95%CI:1·17–3·53).Interpretation: Among adults with newly diagnosed T2DM who smoked, cessation was associated with the lowest risk of coronary events, and switching to e-cigarettes did not reproduce this benefit. Risks of stroke and death in e-cigarette users did not differ from those in quitters, but follow-up was short. E-cigarettes should not be regarded as equivalent to cessation after a diagnosis of T2DM.

  • Open Access

    Artificial Intelligence‐Driven Angiographic Quantification of Fractional Flow Reserve: Proof‐of‐Concept Validation Study

    by Seung Hun Lee, Dong Hyun Gim, Doyeon Hwang, Hyun Kuk Kim, Hyun Cho, Sung Eun Kim, Sung Woo Cho, Ki Hong Choi, Taek Kyu Park, Jeong Hoon Yang, et al.

    Background: Angiography‐based fractional flow reserve (FFR) techniques offer wire‐free alternatives but often require manual segmentation and 3‐dimensional reconstruction. Although an artificial intelligence‐driven approach automates these steps, validation remains limited. This study investigated the diagnostic performance of an artificial intelligence‐driven angiography‐based FFR (medipixel FFR [MPFFR]), compared with quantitative flow ratio (QFR) in predicting functionally significant coronary artery stenosis defined by FFR ≤0.80. Methods: A total of 599 vessels from 452 patients who underwent clinically indicated FFR measurement were prospectively enrolled from 5 university hospitals in Korea. MPFFR used automated processes in frame selection, artificial intelligence contour detection, corresponding points matching, 3‐dimensional reconstruction, and analytical hemodynamic modeling. The primary end point was diagnostic accuracy for detecting FFR ≤0.80. Secondary end points were target vessel failure (composite of cardiac death, target‐vessel myocardial infarction, and target‐vessel revascularization) at 2 years. Results: Mean analysis time of MPFFR was 12.5±1.7 seconds and manual correction was needed in 32 vessels (5.3%). MPFFR showed similar diagnostic performance with QFR (correlation with FFR; MPFFR versus QFR: R=0.885 versus R=0.860, P for comparison=0.011; area under the curve to predict FFR ≤0.80; 0.949 versus 0.953, P for comparison=0.631). At a median follow‐up of 2 years (interquartile range, 1.6–2.6 years), patients with MPFFR ≤0.80 had higher risk of target vessel failure than those with MPFFR >0.80 (4.5% versus 0.8%; adjusted hazard ratio, 5.94 [95% CI, 1.27–27.91]; P =0.024). C‐index to predict target vessel failure was comparable between MPFFR and QFR (0.770 versus 0.753, P for comparison=0.469). Conclusions: In this multicenter registry, an artificial intelligence‐driven angiography‐based FFR demonstrated comparable diagnostic accuracy with QFR in identifying functionally significant stenosis, and similar prognostic ability with QFR in terms of target vessel failure at 2 years. Registration: Multicenter QFR Registry; Unique Identifier: NCT03791788.